

**OFFICIAL**

*b1  
cont*  
~~3. (Amended) The composition according to claim 43, wherein the one or more components of the composition form an erodible matrix.~~

*b2*  
~~4. (Amended) The composition according to claim 43, wherein the one or more components of the composition include an enteric coating.~~

*b2*  
~~8. (Amended) The composition according to claim 43, wherein the one or more components of the composition include an ion exchange resin that forms a complex with the 2'-deoxyadenosine analog.~~

*b2*  
~~9. (Amended) The composition according to claim 43, wherein the one or more components of the composition include micro spheres.~~

*Subj C*  
~~11. (Amended) A method for treating a patient comprising:  
orally administering to the patient a pharmaceutically-effective amount of a composition which is adapted for oral administration and comprises  
a 2'-deoxyadenosine analog which chemically decomposes in an acidic environment of the stomach, and  
an agent which inhibits the 2'-deoxyadenosine analog from decomposing in the acidic environment of the stomach by reducing acid concentration in the stomach.~~

*b2*  
~~12. (Amended) The method according to claim 11 wherein the 2'-deoxyadenosine analog is pentostatin or cladribine.~~

*b2*  
~~13. (Amended) The method according to claim 49, wherein the one or more components of the composition form an erodible matrix.~~

*b2*  
~~14. (Amended) The method according to claim 49, wherein the one or more components of the composition include an enteric coating.~~

*b2  
Subj C*  
~~18. (Amended) The method according to claim 49, wherein the one or more components of the composition comprise an ion exchange resin that forms a complex with the 2'-deoxyadenosine analog.~~

*B7  
cont*  
19. (Amended) The method according to claim 49, wherein the one or more components of the composition comprise micro spheres.

*Subst C1  
B5C*  
21. (Amended) The method according to claim 11 wherein the patient has a disease selected from the group consisting of hematological malignancies, solid tumors sensitive to 2'-deoxyadenosine analogs or adenosine deaminase inhibitors, and autoimmune diseases mediated by adenosine or adenosine deaminase.

*Subst C1  
B6C*  
24. (Amended) The method of claim 11, wherein the orally administering the composition to the patient includes orally administering the composition in a controlled release mechanism.

*Subst C1*  
38. (New) The composition of claim 1, wherein the agent is an H2 inhibitor.

*Subst C1*  
39. (New) The composition of claim 38, wherein the H2 inhibitor is cimetidine.

40. (New) The composition of claim 1, wherein the agent is an acid neutralizer.

*B7*  
41. (New) The composition of claim 40, wherein the acid neutralizer is calcium carbonate.

42. (New) The composition of claim 1, wherein the agent is a proton pump inhibitor.

43. (New) The composition of claim 1, further comprising one or more components of the composition which inhibit the 2'-deoxy adenosine analog from decomposing in the acidic environment of the stomach by isolating the 2'-deoxy adenosine analog from the acidic environment of the stomach.

44. (New) The method of claim 11, wherein the agent is an H2 inhibitor.

45. (New) The method of claim 44, wherein the H2 inhibitor is cimetidine.

46. (New) The method of claim 11, wherein the agent is an acid neutralizer.

47. (New) The method of claim 46, wherein the acid neutralizer is calcium carbonate.

~~CONFIDENTIAL~~

*Searched  
B7  
Cited*

48. (New) The method of claim 11, wherein the agent is a proton pump inhibitor.

49. (New) The method of claim 11, further comprising one or more components of the composition which inhibit the 2'-deoxy adenosine analog from decomposing in the acidic environment of the stomach by isolating the 2'-deoxy adenosine analog from the acidic environment of the stomach.

50. (New) A method for treating a patient comprising:  
orally administering to the patient a pharmaceutically-effective amount of a 2'-deoxyadenosine analog which chemically decomposes in an acidic environment of the stomach,  
and  
administering an agent which inhibits the 2'-deoxyadenosine analog from decomposing in the acidic environment of the stomach by reducing acid concentration in the stomach.

51. (New) The method of claim 50, wherein the agent is administered prior to the oral administration of the 2'-deoxyadenosine analog.

52. (New) The method of claim 50, wherein the agent is co-administered with the 2'-deoxyadenosine analog.

53. (New) The method according to claim 50, wherein the 2'deoxyadenosine analog is pentostatin or cladribine.

54. (New) The method of claim 50, wherein the agent is an H2 inhibitor.

55. (New) The method of claim 54, wherein the H2 inhibitor is cimetidine.

56. (New) The method of claim 50, wherein the agent is an acid neutralizer.

57. (New) The method of claim 56, wherein the acid neutralizer is calcium carbonate.

58. (New) The method of claim 50, wherein the agent is a proton pump inhibitor.